Omeros Corp

Затворен

СекторЗдравеопазване

19.3 1.53

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

18.35

Максимум

19.34

Ключови измерители

By Trading Economics

Приходи

-38M

13M

Продажби

19M

29M

P/E

Средно за сектора

11.485

56.597

EPS

0.02

Марж на печалбата

46.381

Служители

175

EBITDA

-40M

18M

Препоръки

By TipRanks

Препоръки

Купи

12-месечна прогноза

+74.14% upside

Дивиденти

By Acuity

Следващи печалби

12.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

389M

1.4B

Предишно отваряне

17.77

Предишно затваряне

19.3

Настроения в новините

By Acuity

39%

61%

98 / 339 Класиране в Healthcare

Omeros Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

3.09.2026 г., 19:46 ч. UTC

Omeros Corp shares are higher today, supported by a modest upward trend since Wednesday. Easing Treasury yields may contribute to positive market sentiment.

2.09.2026 г., 23:01 ч. UTC

Omeros Corp shares are lower in after-market hours, continuing a downward trend. No specific company news was identified to explain the movement.

1.09.2026 г., 19:16 ч. UTC

Omeros Corp shares are lower today, reflecting a decline since Monday's close amid rising global bond yields and inflationary pressures.

31.08.2026 г., 23:16 ч. UTC

Omeros Corp shares are higher in after-market trading. No specific news was identified to explain this movement, which appears independent of broader market trends.

28.08.2026 г., 20:07 ч. UTC

Omeros Corp shares are lower amid rising U.S. Treasury yields and inflation concerns. The stock peaked early but shifted to a downward trajectory.

27.08.2026 г., 22:01 ч. UTC

Omeros Corp shares are lower in after-market trading, reflecting unusual volatility amid broader market concerns over the Federal Reserve's monetary policy and inflation pressures.

26.08.2026 г., 23:06 ч. UTC

Omeros Corp shares are higher in after-market hours, with no specific news identified. The stock has gained significantly compared to last month's close.

25.08.2026 г., 23:12 ч. UTC

Omeros Corp shares are lower in after-market hours following an unusual trading session, with no specific company news identified to explain the decline.

21.08.2026 г., 19:16 ч. UTC

Omeros Corp shares are higher today, trading above their 20-day moving average, despite no specific news to explain the price action.

20.08.2026 г., 23:32 ч. UTC

Omeros Corp shares are lower in after-market trading, reversing from a high of 0.70% to a low of -1.99%. No specific news was identified.

19.08.2026 г., 22:51 ч. UTC

Omeros Corp shares are trading lower in after-market hours, reaching a session low without any specific news to explain the decline.

18.08.2026 г., 23:16 ч. UTC

Omeros Corp. shares are lower in after-market trading, retracing from earlier gains. This decline coincides with mixed performance in Asian markets amid global economic uncertainties.

17.08.2026 г., 23:06 ч. UTC

Omeros Corp shares are lower in after-market trading, reaching a low of -1.21% before partially recovering. The stock remains above its 20-day moving average.

15.08.2026 г., 00:01 ч. UTC

Omeros Corp shares are higher in after-market trading, reflecting positive momentum as they trade above their 20-day moving average.

14.08.2026 г., 23:41 ч. UTC

Omeros Corp shares are lower in after-market trading, reflecting broader market sentiment amid a surprise decline in U.S. retail sales for July.

13.08.2026 г., 23:06 ч. UTC

Omeros Corp shares are lower in after-market hours, following notable volatility without any specific company news to explain the decline.

12.08.2026 г., 23:51 ч. UTC

News
Social Media

Omeros Corp reported second-quarter revenues of $32.2 million, exceeding expectations. Shares rose in after-market trading following the strong financial results and Medicare approval.

11.08.2026 г., 23:41 ч. UTC

Omeros Corp shares are lower in after-market hours, with no specific news identified to explain the decline. The stock remains above its 20-day moving average.

10.08.2026 г., 23:51 ч. UTC

Omeros Corp shares are lower in after-market hours, influenced by a recent labor report indicating job losses and reduced Fed rate hike expectations.

8.08.2026 г., 00:02 ч. UTC

Omeros Corp shares are lower in after-market hours, showing notable volatility since Friday's close. The stock remains above its 20-day moving average.

7.08.2026 г., 23:31 ч. UTC

Omeros Corp shares are trading lower in after-market hours, despite strong performance in the broader market, particularly among major tech stocks.

6.08.2026 г., 23:01 ч. UTC

Omeros Corp shares are lower in after-market hours, with no specific news identified. Recent economic data may influence expectations of Federal Reserve tightening.

5.08.2026 г., 23:51 ч. UTC

Omeros Corp shares are higher in after-market trading. Broader market sentiment is influenced by disappointing ADP employment data as investors await Non-Farm Payrolls.

4.08.2026 г., 23:02 ч. UTC

Omeros Corp shares are lower in after-hours trading, reversing an initial gain despite strong recent performance above its 20-day moving average.

3.08.2026 г., 23:11 ч. UTC

Event

Omeros Corp shares are lower in after-market trading following the CMS announcement on YARTEMLEA. The stock remains above its 20-day moving average.

1.08.2026 г., 00:01 ч. UTC

Omeros Corp shares are higher in after-market trading, reaching a notable high and staying above the 20-day moving average. No specific news was identified.

31.07.2026 г., 23:41 ч. UTC

Omeros Corp shares are higher in after-market trading, significantly above their 20-day moving average and near the upper end of their one-month range.

30.07.2026 г., 16:06 ч. UTC

Omeros Corp shares are higher today, continuing a steady increase since Wednesday. The stock trades near the upper end of its one-month range.

29.07.2026 г., 18:58 ч. UTC

Social Media

Omeros Corp is trading higher today, driven by positive social media sentiment despite broader weakness in the XBI sector. Market volume remains unusually high.

28.07.2026 г., 19:16 ч. UTC

Social Media

Omeros Corp shares are lower today after earlier declines, amid social media discussions highlighting reduced competition following AstraZeneca's failed trial related to HSCT-TMA.

Сравнение с други в отрасъла

Ценова промяна

Omeros Corp Прогноза

Ценова цел

By TipRanks

74.14% нагоре

12-месечна прогноза

Среден 33 USD  74.14%

Висок 33 USD

Нисък 33 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Omeros Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

1

Купи

1

Задържане

0

Продай

Настроение

By Acuity

98 / 339 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
help-icon Live chat